Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer

Figure 7

Comparison of the estimated IC50 values of Bleomycin, Mitomycin C, Gemcitabine, Cyclopamine, Docetaxel, Cisplatin, Paclitaxel, Rapamycin, Parthenolide, Thapsignargin, Vinblastine, and Doxorubicin in the high- and low-risk BLCA samples by using the GDSC database.